title: A chemical and phosphoproteomic characterization of dasatinib action in lung cancer.
abstract: We describe a strategy for comprehending signaling pathways that are active in lung cancer cells and that are targeted by dasatinib using chemical proteomics to identify direct interacting proteins combined with immunoaffinity purification of tyrosine-phosphorylated peptides corresponding to activated tyrosine kinases. We identified nearly 40 different kinase targets of dasatinib. These include SRC-family kinase (SFK) members (LYN, SRC, FYN, LCK and YES), nonreceptor tyrosine kinases (FRK, BRK and ACK) and receptor tyrosine kinases (Ephrin receptors, DDR1 and EGFR). Using quantitative phosphoproteomics, we identified peptides corresponding to autophosphorylation sites of these tyrosine kinases that are inhibited in a concentration-dependent manner by dasatinib. Using drug-resistant gatekeeper mutants, we show that SFKs (particularly SRC and FYN), as well as EGFR, are relevant targets for dasatinib action. The combined mass spectrometry-based approach described here provides a system-level view of dasatinib action in cancer cells and suggests both functional targets and a rationale for combinatorial therapeutic strategies.
authors.affiliation: Department of Thoracic Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
authors.forename: Jiannong
authors.initials: J
authors.lastname: Li
authors.forename: Uwe
authors.initials: U
authors.lastname: Rix
authors.forename: Bin
authors.initials: B
authors.lastname: Fang
authors.forename: Yun
authors.initials: Y
authors.lastname: Bai
authors.forename: Arthur
authors.initials: A
authors.lastname: Edwards
authors.forename: Jacques
authors.initials: J
authors.lastname: Colinge
authors.forename: Keiryn L
authors.initials: KL
authors.lastname: Bennett
authors.forename: Jingchun
authors.initials: J
authors.lastname: Gao
authors.forename: Lanxi
authors.initials: L
authors.lastname: Song
authors.forename: Steven
authors.initials: S
authors.lastname: Eschrich
authors.forename: Giulio
authors.initials: G
authors.lastname: Superti-Furga
authors.forename: John
authors.initials: J
authors.lastname: Koomen
authors.forename: Eric B
authors.initials: EB
authors.lastname: Haura
mesh_terms: D017209:Apoptosis; D045744:Cell Line, Tumor; D000069439:Dasatinib; D055785:Gene Knockdown Techniques; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D013058:Mass Spectrometry; D010455:Peptides / Q000737:chemistry / Q000378:metabolism; D010641:Phenotype; D010750:Phosphoproteins / Q000737:chemistry* / Q000378:metabolism*; D010766:Phosphorylation / Q000187:drug effects; D011485:Protein Binding; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D040901:Proteomics / Q000379:methods*; D011743:Pyrimidines / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects; D013844:Thiazoles / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D010455:Peptides; D010750:Phosphoproteins; D011743:Pyrimidines; D013844:Thiazoles; D011505:Protein-Tyrosine Kinases; D017346:Protein Serine-Threonine Kinases; D000069439:Dasatinib